Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis
Oncoinvent Solutions AS
Oncoinvent Solutions AS
National Cancer Institute (NCI)
BioNTech SE
MOMA Therapeutics
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
Kivu Bioscience Inc.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Instil Bio
Genentech, Inc.
M.D. Anderson Cancer Center
AstraZeneca
MOMA Therapeutics
Kestrel Therapeutics, Inc.
Chong Kun Dang Pharmaceutical
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Incyte Corporation
Mersana Therapeutics
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
Context Therapeutics Inc.
Nammi Therapeutics Inc
Regor Pharmaceuticals Inc.
OncoC4, Inc.
Compass Therapeutics
Revolution Medicines, Inc.
Kortuc, Inc.
Exscientia AI Limited
Abramson Cancer Center at Penn Medicine
USWM, LLC (dba US WorldMeds)
Seagen Inc.
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
KaliVir Immunotherapeutics
Fate Therapeutics
Conjupro Biotherapeutics, Inc.